You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FGFR2b Overexpression

Showing 1 - 25 of 753
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumors Trial (Bemarituzumab)

Recruiting
  • Solid Tumors
  • Duarte, California
  • +54 more
Feb 1, 2023

Squamous-Cell Non-Small-Cell Lung Cancer Trial in Worldwide (Bemarituzumab, Docetaxel)

Recruiting
  • Squamous-Cell Non-Small-Cell Lung Cancer
  • Orange, California
  • +24 more
Jul 27, 2022

Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York

Recruiting
  • Advanced Solid Tumor
  • +13 more
  • Duarte, California
  • +3 more
Oct 25, 2022

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in Worldwide (Bemarituzumab, mFOLFOX6, Placebo)

Recruiting
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Anchorage, Alaska
  • +140 more
Aug 11, 2022

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in Worldwide (Bemarituzumab, Nivolumab, mFOLFOX6)

Recruiting
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Phoenix, Arizona
  • +119 more
Feb 1, 2023

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma Trial in Taiwan, United States (KIN-3248)

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • La Jolla, California
  • +4 more
Aug 9, 2022

Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma Trial in Canada, Germany, United States (Infigratinib)

Not yet recruiting
  • Advanced Solid Tumor
  • +2 more
  • Palo Alto, California
  • +9 more
Aug 2, 2022

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)

Recruiting
  • Breast Cancer
  • +3 more
  • Stanford, California
    Stanford University
Feb 16, 2022

Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, NSCLC, KRAS Gene Mutation Trial in Santa Monica,

Recruiting
  • Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations
  • +2 more
  • Futibatinib and Binimetinib
  • Santa Monica, California
  • +2 more
Jun 2, 2022

Urothelial Carcinoma Trial in Shanghai (AZD4547)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Cancer Hospital
Oct 20, 2021

Gastric Cancer, Gastroesophageal Junction Cancer Trial in Japan, Korea, Republic of, Taiwan (Bemarituzumab, CAPOX, SOX)

Recruiting
  • Gastric Cancer
  • Gastroesophageal Junction Cancer
  • Northport, New York
  • +13 more
Jan 4, 2023

HER2-positive Breast Cancer, HER2 Low, SYD-985 Trial in Aurora (Vic-trastuzumab duocarmazine (SYD985) + paclitaxel)

Recruiting
  • HER2-positive Breast Cancer
  • +26 more
  • Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
  • Aurora, Colorado
    University of Colorado Cancer Center
Oct 22, 2021

Bladder Cancer Trial (Rogaratinib)

Withdrawn
  • Bladder Cancer
  • (no location specified)
Dec 13, 2019

Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate

Not yet recruiting
  • Cancer of Cervix
  • Apoptosis
  • Immunohistochemistry
  • (no location specified)
Nov 17, 2023

Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression Trial in Worldwide (Data collection and quality of life

Recruiting
  • Cancer
  • +15 more
  • Data collection and quality of life questionnaire
  • Graz, Austria
  • +40 more
Jul 27, 2021

Urothelial Carcinoma Trial in Worldwide (Rogaratinib (BAY1163877), Atezolizumab)

Active, not recruiting
  • Urothelial Carcinoma
  • Tucson, Arizona
  • +29 more
Aug 17, 2022

Solid Tumor Trial in Worldwide (Debio 1347)

Terminated
  • Solid Tumor
  • Debio 1347
  • Scottsdale, Arizona
  • +104 more
Mar 30, 2022

Subjects Treated With ACTR T Cell Product

Terminated
  • B Cell Lymphomas
  • +3 more
  • ACTR T Cell Product
  • Gilbert, Arizona
  • +15 more
Oct 4, 2021

Squamous-cell NSCLC Trial in Switzerland (Rogaratinib)

Active, not recruiting
  • Squamous-cell Non-small Cell Lung Cancer
  • Baden, Switzerland
  • +10 more
Jan 20, 2022

Klotho _ LRP-6 _ Gastric Adenocarcinoma

Not yet recruiting
  • Gastric Adenocarcinoma
  • +2 more
  • Prognostic study
  • (no location specified)
Jan 29, 2023

Gastric Adenocarcinoma Trial in Worldwide (Derazantinib, Derazantinib-paclitaxel-ramucirumab, Derazantinib-atezolizumab)

Completed
  • Gastric Adenocarcinoma
  • Orlando, Florida
  • +80 more
Jan 13, 2023

Urothelial Carcinoma Trial in Worldwide (Derazantinib dose level 1 (300mg once daily) monotherapy, Derazantinib various dose

Completed
  • Urothelial Carcinoma
  • Derazantinib dose level 1 (300mg once daily) monotherapy
  • +4 more
  • Newnan, Georgia
  • +65 more
Oct 19, 2022

Gastric Cancer Trial (Disitamab Vedotin Combined With Sintilimab)

Not yet recruiting
  • Gastric Cancer
  • Disitamab Vedotin Combined With Sintilimab
  • (no location specified)
Jan 31, 2023

Leiomyosarcoma, Liposarcoma, Soft Tissue Sarcoma Adult Trial in Taipei (Eribulin, Lenvatinib)

Active, not recruiting
  • Leiomyosarcoma
  • +3 more
  • Taipei, Taiwan
  • +1 more
Dec 27, 2022

HER2-overexpressed Advanced Solid Tumors After Progression of

Not yet recruiting
  • HER2
  • +3 more
  • Disitamab Vedotin
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Dec 14, 2022